Ignite Creation Date:
2025-12-25 @ 1:24 AM
Ignite Modification Date:
2026-02-25 @ 8:18 PM
Study NCT ID:
NCT02338193
Status:
COMPLETED
Last Update Posted:
2019-06-11
First Post:
2015-01-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011236', 'term': 'Prediabetic State'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C529054', 'term': 'dapagliflozin'}, {'id': 'D008687', 'term': 'Metformin'}], 'ancestors': [{'id': 'D001645', 'term': 'Biguanides'}, {'id': 'D006146', 'term': 'Guanidines'}, {'id': 'D000578', 'term': 'Amidines'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'karen.elkind-hirsch@womans.org', 'phone': '225 231-5278', 'title': 'Dr Karen Elkind-Hirsch, Director of Research', 'organization': "Woman's Hospital"}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}, 'limitationsAndCaveats': {'description': 'Important limitations were the small number completed patients per drug group and only 24 weeks of therapy. Surrogate measures were for central adiposity; use of dual-energy x-ray absorptiometry to measure body composition would increase accuracy'}}, 'adverseEventsModule': {'timeFrame': '6 months while participating in trial', 'eventGroups': [{'id': 'EG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks', 'otherNumAtRisk': 20, 'deathsNumAtRisk': 20, 'otherNumAffected': 6, 'seriousNumAtRisk': 20, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks', 'otherNumAtRisk': 21, 'deathsNumAtRisk': 21, 'otherNumAffected': 6, 'seriousNumAtRisk': 21, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks', 'otherNumAtRisk': 25, 'deathsNumAtRisk': 25, 'otherNumAffected': 5, 'seriousNumAtRisk': 25, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Yeast infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 21, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 25, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Nausea/diarrhea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 20, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 21, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 25, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change in Body Weight', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '-21.5', 'spread': '14', 'groupId': 'OG000'}, {'value': '-12.5', 'spread': '20', 'groupId': 'OG001'}, {'value': '-4.4', 'spread': '18', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.032', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'One Way ANOVA with Bonferroni contrast if p\\>0.05', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': 'Change from baseline (time 0) to study end (24 weeks)', 'description': 'Change in absolute body weight with combination therapy compared to monotherapy from baseline to week 24', 'unitOfMeasure': 'kilograms', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change in Percent Body Weight', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '-4.9', 'spread': '3.1', 'groupId': 'OG000'}, {'value': '-3.2', 'spread': '4.5', 'groupId': 'OG001'}, {'value': '-1.1', 'spread': '4.4', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.05', 'groupIds': ['OG000', 'OG002'], 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'One Way ANOVA with Bonferoni contrast test'}], 'paramType': 'MEAN', 'timeFrame': 'Change from baseline (time 0) to study end (24 weeks)', 'description': 'Change in percent body weight with combination therapy compared to monotherapy from baseline to week 24', 'unitOfMeasure': 'percent weight loss from baseline', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Body Mass Index (BMI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '33', 'spread': '6.2', 'groupId': 'OG000'}, {'value': '33.7', 'spread': '7.7', 'groupId': 'OG001'}, {'value': '31', 'spread': '5.4', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.01', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast test', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'BMI (measure of overall adiposity) in combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'kg/m2', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Waist Circumference (WC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '95.6', 'spread': '12.7', 'groupId': 'OG000'}, {'value': '95', 'spread': '16.6', 'groupId': 'OG001'}, {'value': '91.7', 'spread': '11.4', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.012', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast test', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'Waist size (measure of truncal adiposity)with combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'centimeters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Waist- to -Hip Ratio (WHR; Measure of Central Adiposity)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '0.81', 'spread': '0.055', 'groupId': 'OG000'}, {'value': '0.80', 'spread': '.06', 'groupId': 'OG001'}, {'value': '0.83', 'spread': '.06', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.007', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast test', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'Waist-to-hip ratio with combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Waist-to-height Ratio (WHtR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '0.58', 'spread': '.06', 'groupId': 'OG000'}, {'value': '0.57', 'spread': '.09', 'groupId': 'OG001'}, {'value': '0.56', 'spread': '.06', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '0.023', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'Waist divided by height a( measure of central adiposity) with combination therapy compared to monotherapy after 24 weeks of therapy', 'unitOfMeasure': 'ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Diastolic Blood Pressure (DBP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '79', 'spread': '11', 'groupId': 'OG000'}, {'value': '77.8', 'spread': '11', 'groupId': 'OG001'}, {'value': '79', 'spread': '7.5', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '>0.05', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment)', 'description': 'Diastolic blood pressure with combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'mmHG', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Systolic Blood Pressure (SBP)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '125', 'spread': '12', 'groupId': 'OG000'}, {'value': '124', 'spread': '13', 'groupId': 'OG001'}, {'value': '119.6', 'spread': '10.4', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '>0.05', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'Systolic blood pressure with combination therapy compared to monotherapy after 24 weeks of therapy', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Liver Enzymes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '1.13', 'spread': '.35', 'groupId': 'OG000'}, {'value': '1.12', 'spread': '.32', 'groupId': 'OG001'}, {'value': '1.18', 'spread': '.3', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'ALT/AST ratio with combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'Ratio', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Total Cholesterol Levels (CHOL)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '196', 'spread': '45', 'groupId': 'OG000'}, {'value': '168', 'spread': '32', 'groupId': 'OG001'}, {'value': '178', 'spread': '31', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast test', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'Cholesterol levels with combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Triglyceride (TRG) Levels', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '119', 'spread': '59', 'groupId': 'OG000'}, {'value': '89.8', 'spread': '39', 'groupId': 'OG001'}, {'value': '212', 'spread': '64', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.004', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast test', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'Triglyceride levels with combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Fasting Blood Glucose (FBG)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '89', 'spread': '7.9', 'groupId': 'OG000'}, {'value': '91', 'spread': '9.2', 'groupId': 'OG001'}, {'value': '87', 'spread': '4.3', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.02', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast test', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'Fasting blood glucose levels with combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Mean Blood Glucose (MBG) During an OGTT', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '109.5', 'spread': '15.2', 'groupId': 'OG000'}, {'value': '110.1', 'spread': '17.8', 'groupId': 'OG001'}, {'value': '112.5', 'spread': '15', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.012', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast test', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'Mean blood glucose after glucose load with combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Fasting Insulin Sensitivity (HOMA-IR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '2.6', 'spread': '1.6', 'groupId': 'OG000'}, {'value': '2.4', 'spread': '1.4', 'groupId': 'OG001'}, {'value': '1.8', 'spread': '0.84', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '>0.05', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast test', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'HOMA index of insulin resistance calculated from fasting insulin and glucose with combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'Index', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Matsuda Sensitivity Index (SI OGTT)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '6.0', 'spread': '3.2', 'groupId': 'OG000'}, {'value': '6.3', 'spread': '4.4', 'groupId': 'OG001'}, {'value': '5.42', 'spread': '2.4', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<0.028', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast test', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'Surrogate measure of insulin sensitivity derived from OGTT with combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'Index', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'First Phase Insulin Secretion (IGI/HOMA-IR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '17', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'OG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'OG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '1.7', 'spread': '3.2', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '1.2', 'groupId': 'OG001'}, {'value': '0.77', 'spread': '.53', 'groupId': 'OG002'}]}]}], 'analyses': [{'pValue': '<.03', 'groupIds': ['OG000', 'OG001', 'OG002'], 'groupDescription': 'Factorial repeated measures ANOVA with Bonferroni contrast test', 'statisticalMethod': 'ANOVA', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'MEAN', 'timeFrame': '24 weeks of treatment', 'description': 'Corrected early insulin response to glucose challenge \\[(insulinogenic index (IGI)/ divided by fasting insulin resistance index (HOMA-IR)\\] with combination therapy compared to monotherapy after 24 weeks of treatment', 'unitOfMeasure': 'Index', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'FG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'FG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '20'}, {'groupId': 'FG001', 'numSubjects': '21'}, {'groupId': 'FG002', 'numSubjects': '25'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '17'}, {'groupId': 'FG001', 'numSubjects': '17'}, {'groupId': 'FG002', 'numSubjects': '15'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '10'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '2'}]}, {'type': 'Pregnancy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}]}, {'type': 'Noncompliant with visits', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '7'}]}, {'type': 'moved out of state', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'intolerant of side effects', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}]}], 'recruitmentDetails': "Patients recruited from Woman's Hospital post delivery", 'preAssignmentDetails': '3 patients not randomized since reluctant to take medication'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '20', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '66', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'DAPA/MET XR', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks\n\nDAPA/MET XR: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks'}, {'id': 'BG001', 'title': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks\n\nDAPA: 10 mg dapagliflozin QD for 20-24 weeks'}, {'id': 'BG002', 'title': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the AM, 1000 mg in the PM for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks\n\nMET XR: 1000 mg Metformin XR BID for 20-24 weeks'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '66', 'groupId': 'BG003'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '66', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '66', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Black or African American', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}, {'value': '22', 'groupId': 'BG003'}]}, {'title': 'White', 'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '15', 'groupId': 'BG001'}, {'value': '15', 'groupId': 'BG002'}, {'value': '44', 'groupId': 'BG003'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '66', 'groupId': 'BG003'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'BMI greater than/equal to 25', 'classes': [{'categories': [{'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '66', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'within 1 year postpartum of GDM pregnancy'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2018-08-31', 'size': 498855, 'label': 'Informed Consent Form', 'hasIcf': True, 'hasSap': False, 'filename': 'ICF_000.pdf', 'typeAbbrev': 'ICF', 'uploadDate': '2019-03-12T13:15', 'hasProtocol': False}, {'date': '2018-07-10', 'size': 1155307, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_001.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2019-03-14T11:36', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 69}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-09-22', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-06', 'completionDateStruct': {'date': '2019-03-13', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-06-07', 'studyFirstSubmitDate': '2015-01-07', 'resultsFirstSubmitDate': '2019-03-14', 'studyFirstSubmitQcDate': '2015-01-09', 'lastUpdatePostDateStruct': {'date': '2019-06-11', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-04-05', 'studyFirstPostDateStruct': {'date': '2015-01-14', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2019-04-30', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-02-13', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in Body Weight', 'timeFrame': 'Change from baseline (time 0) to study end (24 weeks)', 'description': 'Change in absolute body weight with combination therapy compared to monotherapy from baseline to week 24'}], 'secondaryOutcomes': [{'measure': 'Change in Percent Body Weight', 'timeFrame': 'Change from baseline (time 0) to study end (24 weeks)', 'description': 'Change in percent body weight with combination therapy compared to monotherapy from baseline to week 24'}, {'measure': 'Body Mass Index (BMI)', 'timeFrame': '24 weeks of treatment', 'description': 'BMI (measure of overall adiposity) in combination therapy compared to monotherapy after 24 weeks of treatment'}, {'measure': 'Waist Circumference (WC)', 'timeFrame': '24 weeks of treatment', 'description': 'Waist size (measure of truncal adiposity)with combination therapy compared to monotherapy after 24 weeks of treatment'}, {'measure': 'Waist- to -Hip Ratio (WHR; Measure of Central Adiposity)', 'timeFrame': '24 weeks of treatment', 'description': 'Waist-to-hip ratio with combination therapy compared to monotherapy after 24 weeks of treatment'}, {'measure': 'Waist-to-height Ratio (WHtR)', 'timeFrame': '24 weeks of treatment', 'description': 'Waist divided by height a( measure of central adiposity) with combination therapy compared to monotherapy after 24 weeks of therapy'}, {'measure': 'Diastolic Blood Pressure (DBP)', 'timeFrame': '24 weeks of treatment)', 'description': 'Diastolic blood pressure with combination therapy compared to monotherapy after 24 weeks of treatment'}, {'measure': 'Systolic Blood Pressure (SBP)', 'timeFrame': '24 weeks of treatment', 'description': 'Systolic blood pressure with combination therapy compared to monotherapy after 24 weeks of therapy'}, {'measure': 'Liver Enzymes', 'timeFrame': '24 weeks of treatment', 'description': 'ALT/AST ratio with combination therapy compared to monotherapy after 24 weeks of treatment'}, {'measure': 'Total Cholesterol Levels (CHOL)', 'timeFrame': '24 weeks of treatment', 'description': 'Cholesterol levels with combination therapy compared to monotherapy after 24 weeks of treatment'}, {'measure': 'Triglyceride (TRG) Levels', 'timeFrame': '24 weeks of treatment', 'description': 'Triglyceride levels with combination therapy compared to monotherapy after 24 weeks of treatment'}, {'measure': 'Fasting Blood Glucose (FBG)', 'timeFrame': '24 weeks of treatment', 'description': 'Fasting blood glucose levels with combination therapy compared to monotherapy after 24 weeks of treatment'}, {'measure': 'Mean Blood Glucose (MBG) During an OGTT', 'timeFrame': '24 weeks of treatment', 'description': 'Mean blood glucose after glucose load with combination therapy compared to monotherapy after 24 weeks of treatment'}, {'measure': 'Fasting Insulin Sensitivity (HOMA-IR)', 'timeFrame': '24 weeks of treatment', 'description': 'HOMA index of insulin resistance calculated from fasting insulin and glucose with combination therapy compared to monotherapy after 24 weeks of treatment'}, {'measure': 'Matsuda Sensitivity Index (SI OGTT)', 'timeFrame': '24 weeks of treatment', 'description': 'Surrogate measure of insulin sensitivity derived from OGTT with combination therapy compared to monotherapy after 24 weeks of treatment'}, {'measure': 'First Phase Insulin Secretion (IGI/HOMA-IR)', 'timeFrame': '24 weeks of treatment', 'description': 'Corrected early insulin response to glucose challenge \\[(insulinogenic index (IGI)/ divided by fasting insulin resistance index (HOMA-IR)\\] with combination therapy compared to monotherapy after 24 weeks of treatment'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['GDM', 'T2DM', 'prediabetes'], 'conditions': ['Diabetes Prevention in Women After GDM Who Are at High-risk']}, 'referencesModule': {'references': [{'pmid': '33345876', 'type': 'DERIVED', 'citation': 'Elkind-Hirsch KE, Seidemann E, Harris R. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus. Am J Obstet Gynecol MFM. 2020 Aug;2(3):100139. doi: 10.1016/j.ajogmf.2020.100139. Epub 2020 May 16.'}]}, 'descriptionModule': {'briefSummary': 'Women with a history of gestational diabetes (GDM) are at substantially increased risk of type 2 diabetes mellitus (T2DM). Compared with the general population, these women are more likely to be overweight or obese. Moreover, weight gain after GDM is significantly associated with T2DM, independent of baseline body weight. Weight gain, particularly increased central adiposity after delivery, is strongly associated with deterioration of β-cell compensation for insulin resistance. Taken together, our findings and other studies support increased abdominal fat as the strongest factor associated with declining B-cell compensation for insulin resistance in prior GDM women at high risk for T2DM. Dapagliflozin is a novel highly selective SGLT2 inhibitor that improves glycemic control by reducing renal glucose reabsorption leading to urinary glucose excretion. Its efficacy and safety has been studied in multiple randomized controlled trials including an add-on to metformin compared with a placebo. To the extent that glucotoxicity contributes to the demise in β-cell function in subjects with impaired glucose, SGLT2 inhibitors also may prove useful in the treatment of "prediabetes." An additional secondary benefit of SGLT2 inhibition is the elimination of calories in the form of glucose. The loss of glucose with attendant caloric loss contributes to weight loss; in addition, improvements in β cell function have been seen. Weight loss seen with SGLT2 inhibitors is similar to that seen with glucagon-like peptide 1 analogs, and may be more acceptable because they are oral agents. A consistent finding in all dapagliflozin studies has been a reduction in blood pressure. The investigators hypothesize that combination dapagliflozin -metformin treatment over a 24-week period will have a greater positive impact on body weight, anthropometric measurements and glycemic and cardiometabolic parameters than dapagliflozin or metformin monotherapy in overweight/obese at-risk women with a history of GDM.', 'detailedDescription': 'Following written consent, all study patients will undergo the following clinical, metabolic and laboratory evaluations before and during treatment. To ensure that patients remain unidentified, all study subjects will be assigned an individual study identifier which includes the study acronym, patient initials, and unique number. All blood samples will be obtained and results identified and reported using this unique study identifier. A full physical examination will be performed and vital signs (blood pressure, respiration and temperature) determined. Trained personnel using standardized protocols at the baseline and follow-up examination will obtain anthropometric measurements and blood specimens. Absolute body weight, height, waist and hip circumference, body fat distribution (waist/hip {WHR}) and waist/height ratio ({WHtR}) and blood pressure (BP) will be determined. Body weight will be measured to the nearest 0.1 kg using a calibrated digital scale with participants in light clothing and no shoes. Height will be measured to the nearest centimeter. The total body adiposity (total fatness), defined as the accumulation of body fat without regard to regional distribution, will be expressed as BMI and calculated as weight (kg)/ height (m) 2. The circumference measurements will be taken in the upright position using a 15-mm width flexible metric tape held close to the body but not tight enough to indent the skin. Waist circumference (WC) will be measured at the narrowest level midway between the lowest ribs and the iliac crest and hip circumference measured at the widest level over the buttocks while the subjects are standing and breathing normally. The WHR and WHtR will be calculated for measure of body fat distribution.\n\nAll patients will randomly be assigned to one of 3 medication treatment groups-- dapagliflozin-metformin (DAP-MET; 5 mg DAP/ MET 1000 mg BID), metformin XR (MET 1000 mg BID) or dapagliflozin (DAP 10 mg QD); all subjects will be allocated to one of these 3 groups based on computer-generated random numbers using a block randomization method. Oral glucose tolerance tests (OGTTs) with glucose (G) and insulin (I) measured at 0, 30, 60, and 120 after glucose load to assess diabetes, fasting (FBG) and mean blood glucose (MBG) concentrations, insulin resistance and pancreatic ß-cell function will be performed prior to randomization and at 20-24 weeks after full doses of study medications are reached. Mean blood glucose (MBG) concentrations will be calculated by summing glucose values obtained at 0,30,60 and 120 minutes during the OGTT and dividing by 4. At the initial lab evaluation, creatinine and calculated eGFR, TSH, and ß-hCG will be determined for study inclusion. Baseline blood samples will also be analyzed for lipid profiles and liver enzymes.\n\nAll patients will receive the same counseling concerning the benefits of lifestyle modification through diet and exercise. The patients will be also encouraged to increase daily exercise (such as walking, using stairs), although this will not be formally assessed. The participants will receive further encouragement to adhere to the regime during follow-up phone calls. Side effects of the treatment and reason for any withdrawals from the study will be recorded.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT'], 'maximumAge': '45 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* • Overweight/obese (BMI \\>25) females 18 years to 45 years of age, who experienced gestational diabetes (GDM) during recent (within 12 months) pregnancy\n\n * postpartum metabolic abnormalities determined by a 75 g oral glucose tolerance test (Inclusive of prior GDM women with impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or both (IFG/IGT) postpartum)\n * Completed lactation\n * Using adequate contraception during study period unless sterilized\n * Written consent for participation in the study\n\nExclusion Criteria:\n\n* Cholestasis during the past pregnancy\n* Any hepatic diseases in the past (viral hepatitis, toxic hepatic damage, jaundice of unknown etiology), gallstones, abnormal liver function tests or renal impairment (elevated serum creatinine levels or abnormal creatinine clearance\n* Presence of significant systemic disease, heart problems including congestive heart failure, history of pancreatitis, or diabetes mellitus (Type 1 or 2)\n* Renal impairment (e.g., serum creatinine levels ≥1.4 mg/dL for women, or eGFR \\<60)\n* Significantly elevated triglyceride levels (fasting triglyceride \\> 400 mg %)\n* Untreated or poorly controlled hypertension (sitting blood pressure \\>160/95mm Hg)\n* Prior history of a malignant disease requiring chemotherapy\n* Known hypersensitivity or contraindications to use of insulin sensitizers such as metformin or thiazolidinediones\n* History of hypersensitivity reaction to dapagliflozin or other SGLT2 inhibitors (e.g. anaphylaxis, angioedema, exfoliative skin conditions)\n* Current use of metformin, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors or weight loss medications (prescription or OTC)\n* Uncontrolled thyroid disease (documented normal TSH) or hyperprolactinemia\n* Liver enzymes (serum alanine aminotransferase \\[ALT\\] and/or aspartate aminotransferase \\[AST\\] ) levels exceeding more than twice normal lab values\n* Use of drugs known to exacerbate glucose tolerance\n* History of diabetes or prior use of medications to treat diabetes except GDM\n* Currently lactating\n* Eating disorders (anorexia, bulimia) or gastrointestinal disorders\n* Suspected pregnancy (documented negative serum pregnancy test within 72 hours before first dose of study drug), desiring pregnancy in next 6 months, breastfeeding, or known pregnancy in last 2 months\n* Active or prior history of substance abuse (smoke or tobacco use within past 3 years) or significant intake of alcohol or history of alcoholism\n* Patient not willing to use adequate contraception during study period and up to 4 weeks after last dose of study drug (unless sterilized).\n* Debilitating psychiatric disorder such as psychosis or neurological condition that might confound outcome variables\n* Inability or refusal to comply with protocol\n* Not currently participating or having participated in an experimental drug study in previous three months'}, 'identificationModule': {'nctId': 'NCT02338193', 'acronym': 'DAPA-GDM', 'briefTitle': 'Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women', 'organization': {'class': 'OTHER', 'fullName': "Woman's"}, 'officialTitle': 'A Randomized Study Evaluating Dapagliflozin and Metformin, Alone and in Combination, in Overweight Women With a Recent History of Gestational Diabetes Mellitus: Effects on Anthropometric Measurements and Cardiometabolic Abnormalities', 'orgStudyIdInfo': {'id': 'RP-14-012'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'DAPA/MET Extended Release (XR)', 'description': 'Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks', 'interventionNames': ['Drug: DAPA/MET XR']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Dapaglifloxin', 'description': 'Dapagliflozin- 10 mg once daily before first meal for 24 weeks', 'interventionNames': ['Drug: DAPA']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Metformin XR', 'description': 'Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the morning (AM), 1000 mg in the evening ( PM) for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks', 'interventionNames': ['Drug: MET XR']}], 'interventions': [{'name': 'DAPA/MET XR', 'type': 'DRUG', 'otherNames': ['Xigduo 5mg/1000 mg'], 'description': 'final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks', 'armGroupLabels': ['DAPA/MET Extended Release (XR)']}, {'name': 'DAPA', 'type': 'DRUG', 'otherNames': ['Farxiga 10 mg'], 'description': '10 mg dapagliflozin QD for 20-24 weeks', 'armGroupLabels': ['Dapaglifloxin']}, {'name': 'MET XR', 'type': 'DRUG', 'otherNames': ['Glucophage XR 500 mg'], 'description': '1000 mg Metformin XR BID for 20-24 weeks', 'armGroupLabels': ['Metformin XR']}]}, 'contactsLocationsModule': {'locations': [{'zip': '70815', 'city': 'Baton Rouge', 'state': 'Louisiana', 'country': 'United States', 'facility': "Woman's Hospital", 'geoPoint': {'lat': 30.44332, 'lon': -91.18747}}], 'overallOfficials': [{'name': 'Karen E Elkind-Hirsch, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Woman's Hospital, Louisiana"}, {'name': 'Renee Harris, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Woman's Hospital, Louisiana"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'Will publish findings. Individual patient information will be revealed only to patient'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': "Woman's", 'class': 'OTHER'}, 'collaborators': [{'name': 'AstraZeneca', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Director of Research', 'investigatorFullName': 'Karen Elkind-Hirsch', 'investigatorAffiliation': "Woman's"}}}}